Patients with germline BRCA1/2 mutation-associated HER2-negative BC undergoing treatment in the first- through third-line of therapy were randomized to receive either olaparib or chemotherapy in the phase-3 OLYMPIAD trial [115]. This evidence concerns the gene ERBB2 and breast cancer.